Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

2025-524939-39-02

EU Clinical Trials Information System

Trial ID
T-ctis-2025-524939-39-02
Registry
EU Clinical Trials Information System
CTIS number
2025-524939-39-02
Asset
psilocybin (investigator-led; PEX010)
Sponsor, as registered
Slagelse Hospital
Phase
Therapeutic exploratory (Phase II)
Indication
Anorexia nervosa
Status
Authorised
Primary completion
CTIS does not publish one.
Member states concerned
Denmark
Sites
1

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-09-08

Notes on the record

Decision date 2026-08-01, record published 2026-08-02. totalNumberEnrolled 62. New trial authorised on the third submission of its initial application (suffix -02 is the resubmission count per EMA Sponsor Handbook v6.4 section 2.7.2). No ClinicalTrials.gov record found 2026-09-08. Read from the CTIS public API. countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded in this table; see data/decisions.csv.

Company

Through psilocybin (investigator-led; PEX010): Slagelse Hospital

Cited in

Issues quoting 2025-524939-39-02 in their own text.